Research advances toward more effective, long-lasting and side effect-free cancer treatments The Baylor team is building the case for SRC-3 as a promising therapeutic target for next-generation cancer immunotherapy.

Drs. Sang Jun Han, D. Lonard et al are building the case for #SRC3 as a promising #therapeuticTarget for next-generation #cancer #immunotherapy. #Oncoimmunology @tandfonline.bsky.social @bcmhouston.bsky.social #BCMCancerCenter #HotTumor #ColdTumor blogs.bcm.edu/2026/03/26/f...